New study checks if immunotherapy drug durvalumab helps lung cancer patients after standard treatment
NCT ID NCT07309211
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety and effectiveness of the immunotherapy drug durvalumab in 25 people with limited-stage small cell lung cancer who have already had chemotherapy and radiation. The drug is given as a follow-up treatment to try to keep the cancer from coming back. Researchers will track side effects and how long patients live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (an immunotherapy drug)
- What this could lead to
- If successful, this could show that durvalumab is safe and effective after sequential chemoradiotherapy, offering a new treatment option for limited-stage small cell lung cancer.
- What could go wrong
- This is a small, retrospective study with only 25 patients, so results may not apply broadly. The drug may cause serious side effects, and the study does not compare durvalumab to a placebo or other treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, China
-
Nanjing Chest Hospital
NOT_YET_RECRUITINGNanjing, China
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, China
-
The affiliated hospital of qingdao university
RECRUITINGQingdao, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.